Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 89.75%
March 31, 2026 85.05%
December 31, 2025 85.48%
September 30, 2025 87.24%
June 30, 2025 86.26%
March 31, 2025 85.62%
December 31, 2024 85.92%
September 30, 2024 85.36%
June 30, 2024 80.44%
March 31, 2024 71.23%
December 31, 2023 60.67%
September 30, 2023 47.47%
June 30, 2023 44.65%
March 31, 2023 47.91%
December 31, 2022 41.31%
September 30, 2022 55.08%
June 30, 2022 60.23%
March 31, 2022 57.41%
December 31, 2021 77.09%
September 30, 2021 56.51%
June 30, 2021 62.31%
March 31, 2021 71.13%
December 31, 2020 59.37%
September 30, 2020 18.88%
June 30, 2020 1.06%
Date Value
March 31, 2020 -1.36%
December 31, 2019 29.40%
September 30, 2019 -230.3%
June 30, 2019 -89.56%
March 31, 2019 64.44%
December 31, 2018 60.02%
September 30, 2018 71.72%
June 30, 2018 74.36%
March 31, 2018 79.06%
December 31, 2017 75.28%
September 30, 2017 74.85%
June 30, 2017 76.88%
March 31, 2017 70.52%
December 31, 2016 73.82%
September 30, 2016 74.25%
June 30, 2016 70.65%
March 31, 2016 70.00%
December 31, 2015 63.90%
September 30, 2015 59.77%
June 30, 2015 52.68%
March 31, 2015 47.97%
December 31, 2014 -2.06%
September 30, 2014 -35.02%
June 30, 2014 -25.90%
March 31, 2014 -10.32%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Abbott Laboratories 52.64%
AngioDynamics, Inc. 56.00%
Alphatec Holdings, Inc. 62.90%
AtriCure, Inc. 76.75%
Baxter International, Inc. 33.55%